View
217
Download
0
Category
Preview:
Citation preview
Issue 3 : September– December 2013
CRC’s OBJECTIVE 1. To promote a culture of research among healthcare workers in Sabah. 2. To disseminate skills in Methodology, Statistical tools, and techniques in designing and conducting clinical trials. 3. To provide healthcare workers the principle of methodology and biostatistics in clinical research
Warmest Greeting from CRC Sabah! Welcome 2014, and Happy New Year! As we begin this New Year, we hope that 2014 will bring bigger and better things for the Clinical Research Centre (CRC).
In This issue, we want to announce the upcoming workshop organized by CRC Sabah for the year 2014.
1. Good Clinical Practice (GCP) Workshop collaboration with Clinical Research Malaysia (CRM) 19th – 21st Feb 2014, Sabah Women and Children Hospital.
2. Sabah Good Clinical Practice (GCP) Workshop 26th – 28th Mar 2014, Hospital Queen Elizabeth II.
3. Basic to Intermediate Medical Biostatistics Using SPSS Workshop 2014 14 – 17 April 2014, School Of Medical, University Malaysia Sabah (UMS).
4. Advanced Medical Biostatistics Using SPSS Workshop 2014 2 – 6 Jun 2014, School Of Medical, University Malaysia Sabah (UMS).
Grab this opportunity and never stop Learning! See you there!
To be a leading clinical research institution in Asia
To improve patients health outcomes through ethical
and quality clinical research.
CRC SABAH NEWSLETTER
Inside This Issue
Welcome to Issue 3 of CRC Sabah Newletter
Investigator Initiated Research (IIR) and industry Sponsored Research (ISR) updates
Activities and Photo Gallery
Contact Us
Upcoming Events
CRC’s Vision
CRC’s Mission
WELCOME TO ISSUE 3 OF CRC NEWSLETTER
ISSUE 3: September – December 2013 CRC Sabah Newsletter
MESSAGE AND RESOLUTION CRC SABAH HEAD 2014
First and foremost, I would like to congratulate the editorial team for their success in publishing the third edition of CRC Sabah Newsletter. This latest edition marks another important milestone for CRC Sabah. It has been more than 5 years since the inception of CRC Sabah. Since then we have seen the number of industry-sponsored research and investigator-initiated research activities increase. CRC Sabah is committed to promote a research culture at all levels of the MOH in Sabah. In order to achieve this CRC Sabah has visited 13 district hospitals in the north, west and interior of Sabah. These visit helped to promote CRC services and resolve problems with regard to research matters in the districts. CRC Sabah will cover the hospitals in eastern Sabah this year.
In addition, CRC will organize numerous courses such as a Biostatistics Workshop, Research Proposal Development workshop and Good Clinical Practice workshop. This is to disseminate information to healthcare providers the proper way of conducting research. We hope to strengthen research capability through long lasting collaborations with local institutions and other hospitals. Additionally, we hope to facilitate research activities with emphasis on quality research from these collaborations.
Finally, I wish to thank all the staff of CRC Sabah for working tirelessly to achieve these objectives. Enjoy reading.
Datuk Dr Jayaram Menon Head of CRC Sabah Hospital Queen Elizabeth
Thank you for the opportunity to say a few words.
Congratulations to the editorial team from CRC Likas for producing the third edition of CRC Sabah Newsletter.
2013 has seen a number of successful industry sponsored research (ISR), which is the main focus at our centre. A Good Clinical Practice (GCP) Workshop will be held from 19-21 February 2014 in Likas Hospital itself, specially organised by Clinical Research Malaysia (CRM) in collaboration with CRC Sabah.
We hope to increase awareness in clinical research as well as to cultivate the research culture and have responsible investigators to conduct studies of high quality. We are committed to assist all the disciplines which are interested to conduct research, within our capabilities. Last but not least, I wish everyone a happy new year!
Dr Flora Chong Li Tze Head of CRC Hospital Likas
ISSUE 3: September – December 2013 CRC Sabah Newsletter
NO
NMRR ID
STUDY TITLE
STUDY SITE
1 NMRR-13-425-14815 Substance use among psychiatric inpatients in Duchess of Kent Hospital, Sandakan
Duchess of Kent Hospital, Sandakan
2 NMRR-13-354-16253 Amalan Gaya Hidup Sihat di Kalangan Paramedik Hospital Kuala Penyu
Kuala Penyu Hospital
3 NMRR-13-546-16814
Attitude and Perceptions of Healthcare Professionals towards Clinical Pharmacy Services in Lahad Datu Hospital
Lahad Datu Hospital
4 NMRR-12-134-13359
Mengkaji faktor-faktor yang mempengaruhi kesan psikososial terhadap pesakit talasemia.
QEH I/ Keningau/ HWKKS
5 NMRR-13-677-15713
Determining the Aetiology of Non-Malarial Acute Febrile Illness in Sabah QEH I/ HWKKS/ Kudat/Kota Merudu
6 NMRR-13-574-16749 CD44s expression in soft tissue sarcomas, a potential prognostic marker QEH I
7 NMRR-13-858-14725
The study of b-Thalassemia trait among adolescents in sabah, east malaysia, a population study
QEH I
8 NMRR-13-800-15838
Survey on knowledge of psychotropic medications among paramedics and nurses in Hospital Mesra Bukit Padang
HMBP
9 NMRR-13-804-16974 Risk factors of pacemaker Implantation Infection: a single centre experience. QEH II
10 NMRR-13-813-17173
Amalan kepatuhan rawatan tibi secara dot dalam kalangan pesakit tibi di Klinik kawalan tibi dan kusta Lahad Datu, Sabah.
Jabatan Pesakit Luar, Klinik Kesihatan Lahad Datu
11 NMRR-13-842-17444
Census on patients completing one year treatment of adjuvant Trastuzumab from January 2012 till July 2013 at Hospital Likas, Kota Kinabalu, Sabah.
HWKKS
12 NMRR-13-800-15838
Survey on knowledge of psychotropic medications among paramedics and nurses in Hospital Mesra Bukit Padang
HMBP
13 NMRR-13-804-16974 Risk factors of pacemaker Implantation Infection: a single centre experience. QEH II
14 NMRR-13-842-17444 Census on patients completing one year treatment of adjuvant Trastuzumab
from January 2012 till July 2013 at Hospital Likas, Kota Kinabalu, Sabah. HWKKS
15 NMRR-13-639-16766 A Randomized Controlled Study on Compliance towards MASA 1956 among Retail Pharmacies in Sabah
Cawangan Penguatkuasa Farmasi, Jabatan Kesihatan Negeri Sabah.
16 NMRR-13-649-16823 A Pilot Study of Barriers Towards Quit Smoking among Participants of Quit Smoking Clinic in Hospital Duchess of Kent, Sandakan.
HDOK
17 NMRR-13-732-16497 Implementation of hospital information system (his) in Malaysian public hospitals
Kunak/ Keningau/ Lahad datu Hosp
18 NMRR-13-843-16712
Human-animal Exposure Study in Malaysia, Kinabatangan District, Sabah State, Malaysia
JKNS
19 NMRR-13-906-16967
Epidemiological and Clinical Profile of Transfusion Dependent Thalassemia Patient in Sabah
QEH I/ HDOK
Table 1: Investigator Initiated Research (IIR) Approved by MREC
ISSUE 3: September – December 2013 CRC Sabah Newsletter
20 NMRR-13-1192-18473
Neonatal jaundis teruk: kegagalan ibu mematuhi rujukan pemeriksaan serum bilirubin mengakibatkan peningkatan kes neonatal jaundis teruk di daerah Sandakan.
Pejabat Kesihatan Kawasan Sandakan
21 NMRR-13-642-17166 Outcome of Pharmacist Intervention on Medication Compliance among Hemodialysis patients in Lahad Datu Hospital
Lahad Datu Hosp
22 NMRR-13-875-17115 Fluoride enamel opacities among 16-year-old school children in Malaysia
Oral Health Division, MOH, JKNS
23 NMRR-13-962-17898 Cardiovascular risk management among primary care patients in Malaysia Klinik Kesihatan Luyang
24 NMRR-13-915-16059
A retrospective Assessment of Integrated-Quit-Smoking-Service in Primary Healthcare Setting
Klinik Kesihatan Luyang
25 NMRR-13-373-14897 Current status of Drug Information Centers in Malaysia JKNS
26 NMRR-13-891-17366 DEB-only All Comers Registry QEH II
27 NMRR-13-904-16833
HER-2 Expression and Amplification in locally advanced, metastatic or unresectable gastric and gastroesophageal junction adenocarcinoma population in PPNR, Sabah.
HWKKS
28 NMRR-13-1001-15684
The Effectiveness of Online Training for Interpretation of Video fluoroscopy of Swallowing Study Among Speech-Language Therapists in Malaysia.
QEH I/ HDOK
29 NMRR-13-883-16902 Program Pengubatan Beramai-ramai (MDA) Filariasis Limfatik Penduduk Di Kampung Keramat, Beluran, Sabah.
Pejabat Kesihatan Kawasan Beluran
30 NMRR-13-725-16306
Isolation of methicillin-resistant staphylococcus aureus (mrsa) from nasal swab in heterogenous studied group population
QEH I
31 NMRR-13-599-16838
Medication therapy optimization clinic (mtoc) dyslipidemia: evaluation of a pharmacist-managed lipid clinic that uses a novel lipid titration protocol
Tawau Hospital
32 NMRR-13-551-16402 Liver impairment in paediatric thalassaemia patients on deferasirox HDOK
33 NMRR-13-1066-17354
International multicentre prevalence study on sepsis QEH I/ QEH II/ Keningau/ HDOK/ Lahad Datu
34 NMRR-13-1088-17518
Psychometric evaluation of the malay version of alcohol use disorder identification test (audit-m)
Klinik Kesihatan Penampang
35 NMRR-13-1092-16922
Physician's satisfaction with the performance of pharmacists in pharmacist-involved anticoagulation clinic, Queen Elizabeth Hospital II
QEH II
36 NMRR-13-1023-14660
Identifying psychosocial and economic risk factors and quantifying the costs of age-related cognitive impairment: implications of population aging in Malaysia
QEH I
37 NMRR-13-1195-17901
Pharmacist-initiated lung function screening using validated copd-ps questionnaire followed by vitalograph copd-6 to detect the impaired lung function in people at risk of developing COPD in primary health care setting.
Klinik Kesihatan Luyang
38 NMRR-13-1167-18340
Kajian dalam dokumentasi penjagaaan pesakit yang menyebabkan bebanan di kalangan jururawat di Queen Elizabeth Hospital II
QEH II
ISSUE 3: September – December 2013 CRC Sabah Newsletter
NO NMRR ID Department/ Unit
Site Institution
Research Title
Research Subtype
1 NMRR-08-1377-2750
Oncology
HWKKS
Multicenter, randomized, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard pemetrexed therapy compared to placebo plus
Interventional Study : Clinical Trial
2 NMRR-09-200-3744
Rheumatology HQE I
A Long-Term, Open-Label Follow-Up Study of Tofacitinib (CP-690,550) For Treatment of Rheumatoid Arthritis. Protocol No. A3921024
Interventional Study : Clinical Trial
3 NMRR-09-401-4109
Rheumatology HQE I
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFá Monoclonal Antibody, Administered Intravenously, in Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy.
Interventional Study : Clinical Trial
4 NMRR-09-654-4406
Oncology HWKKS
A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-Type KRAS, Metastatic Colorectal Cancer
Interventional Study : Clinical Trial
5 NMRR-10-628-5357
Nephrology HQE I
Phase IIb/III Clinical Study Protocol - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) -
Interventional Study : Clinical Trial
6 NMRR-10-198-5403
Cardiology HQE II
Prospective observational LongitudinAl Registry oF patients with stable coronary arterY disease.
Observational Study : Patient registry/Clinical database
7 NMRR-10-1193-5556
Rheumatology HQE I
An observational study of Rheumatoid arthritis patients on adalimumab to Evaluate quality of LIfe Variables, Effects on work productivity and functional outcomes in Malaysia
Observational Study : Clinical Economics
8 NMRR-10-706-6055
Endocrinology HQE I
A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk.
Interventional Study : Clinical Trial
9 NMRR-10-753-6795
PSY HMBP
A Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Interventional Study : Clinical Trial
10 NMRR-10-983-7456
Rheumatology HQE I
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE)
Interventional Study : Clinical Trial
11 NMRR-10-1203-7871
Rheumatology HQE I A randomized, double-blind, parallel-group study of safety and the effect on clinical outcome of Tocilizumab SC versus placebo SC in combination with traditional disease modifying anti-rheumatic drugs (DMARDs) in patients with moderate to severe active rheumatoid arthritis
Interventional Study : Clinical Trial
12 NMRR-11-395-9024
Oncology HWKKS A Open-Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy
Interventional Study : Clinical Trial
13 NMRR-11-991-9842
Oncology HWKKS A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 ìg Once-Every-3-
Interventional Study : Clinical Trial
Table 2 : Ongoing Industry Sponsored Research (ISR) In Sabah. August – December 2013
ISSUE 3: September – December 2013 CRC Sabah Newsletter
Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
14 NMRR-11-
865-9930
Pathology HQE I Scientific Partnership for HER2 Testing Excellence (SPHERE) Clinical Audit
Observational Study : Patient registry/Clinical database
15 NMRR-11-800-10093
ENT/ Haematology/ Oncology
HQE I/ HWKKS
Cancer and its economic impact on household in the Asean countries (action study)
Observational Study : Patient registry/Clinical database
16 NMRR-11-1020-10569
Oncology HWKKS A phase iii prospective, two-cohort non-randomized, multi-centre, multinational, open label study to assess the safety of assisted- and self-administered subcutaneous Trastuzumab as therapy in patients with operable her2-positive early breast cancer
Interventional Study : Clinical Trial
17 NMRR-11-1010-10697
Gastroenterology HQE I A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Interventional Study : Clinical Trial
18 NMRR-12-50-10793
Pediatrics HWKKS A hospital-based, retrospective study of the burden of community acquired pneumonia in children aged <5 years in Indonesia, Malaysia, South Korea and Vietnam
19 NMRR-12-181-10976
Gastroenterology HQE I A Multi-centre, Randomised, Double-blind, Placebo-controlled Trial to Determine the Efficacy and Safety of Hepar-P Capsule for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventional Study : Clinical Trial
20 NMRR-12-426-11014
Rheumatology HQE I A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X)
Interventional Study : Clinical Trial
21 NMRR-12-493-11112
Respiratory HQE I A randomized, double-blind, double-dummy, 4-week treatment, parallel-group study to evaluate the efficacy and safety of two doses of Mometasone furoate delivered via Concept1 or Twisthaler® in adult and adolescent patients with persistent asthma
Interventional Study : Clinical Trial
22 NMRR-12-322-11499
Rheumatology HQE I A randomized, double-blind placebo-controlled study of the maintenance of efficacy of Atanercept plus dmard(s) compared with dmard(s) alone in subjects with rheumatoid arthritis after achieving an adequate response with etanercept plus dmard(s).
Interventional Study : Clinical Trial
23 NMRR-12-419-12390
Oncology HWKKS A randomized, multicenter, adaptive phase ii/iii study to evaluate the efficacy and safety of Trastuzumab Emtansine (t-dm1) versus Taxane (Docetaxel or Paclitaxel) in patients with previously treated locally advanced or metastatic her2-positive gastric cancer, including adenocarcinoma of the Gastroesophageal junction
Interventional Study : Clinical Trial
24 NMRR-12-715-12597
Cardiology HQE II A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease
Interventional Study : Clinical Trial
25 NMRR-12-914-12832
Oncology HWKKS A randomized, phase iii, multicenter, double-blind, placebo-controlled study evaluating the efficacy and safety of Onartuzumab (metmab) in combination with 5-fluorouracil, folinic acid, and oxaliplatin (mfolfox6) in
Interventional Study : Clinical Trial
ISSUE 3: September – December 2013 CRC Sabah Newsletter
patients with metastatic her2-negative, met-positive Gastroesophageal cancer
26 NMRR-12-690-13000
Cardiology HQE II Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) Prospective Observational Registry
Observational Study : Clinical Epidemiology
27 NMRR-12-770-13097
O&G HWKKS A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women
Interventional Study : Clinical Trial
28 NMRR-12-826-13119
PSY HMBP A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Trial to Evaluvate the Efficacy, Safety, and Tolerability of Brexpiprazole(OPC-34712) as Maintenance Treatment in Adults with Schizophrenia
Interventional Study : Clinical Trial
29 NMRR-12-900-13137
Haematology HQE I A randomized, open-label, multi-centre study to evaluate patient preference with subcutaneous administration of rituximab versus intravenous rituximab in previously untreated patients with cd20+ diffuse large b-cell lymphoma or cd20+ follicular non-Hodgkin's lymphoma grades 1, 2 or 3a
Interventional Study : Clinical Trial
30 NMRR-12-1102-13587
Cardiology HQE II A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the ocurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Interventional Study : Clinical Trial
31 NMRR-12-1096-13654
Oncology HWKKS A double-blind, placebo-controlled, randomized, multicenter phase iii study evaluating the efficacy and safety of Pertuzumab in combination with Trastuzumab and chemotherapy in patients with her2-positive metastatic Gastroesophageal junction and gastric cancer
Interventional Study : Clinical Trial
33 NMRR-12-1071-13841
Rheumatology HQE I A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody- Positive Systemic Lupus Erythematosus Receiving Belimumab
Observational Study : Clinical Economics
34 NMRR-12-1283-14486
Oncology HWKKS A phase IIIb, multi-center, open-label, expanded access study of Everolimus (RAD001) in combination with Exemestane in post-menopausal women with Estrogen receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer EVEREXES
Interventional Study : Clinical Trial
35 NMRR-13-58-14559
Opthalmology HQE I "Prospective, double-blind, placebo-controlled, randomized, parallel-group, multi-center study with an open-label extension period to investigate the efficacy and safety of two different doses of NT 201 in Botulinum toxin treatment-naïve subjects with Blepharospasm"
Interventional Study : Clinical Trial
36 NMRR-13-54-14597
Pediatrics HWKKS Understanding Adherence, Stigma, and Behavioral Risk Factors of Adolescents in the TREAT Asia Pediatric HIV Observational Database using an Audio Computer-Assisted Self Interview (TApHOD ACASI)
Observational Study : Patient registry/Clinical database
37 NMRR-13-127-14699
Oncology HWKKS A three-arm, randomized, open label, phase II study of Everolimus in combination with Exemestane versus Everolimus alone versus Capecitabine in the treatment of postmenopausal women with estrogen receptor positive, locally advanced, recurrent, or metastatic
Interventional Study : Clinical Trial
ISSUE 3: September – December 2013 CRC Sabah Newsletter
breast cancer after recurrence or progression on prior letrozole or anastrozole
38 NMRR-13-197-14838
Gen Medical Keningau Hospital
An International Survey on Hypoglycaemia among Insulin-treated Patients with Diabetes - Non Interventional study
Observational Study : Patient registry/Clinical database
39 NMRR-13-96-15078
Gen Medical Keningau Hospital
DiabCare Asia 2012 - Malaysia A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of patients with type 2 diabetes in Malaysia Non-Interventional study
Observational Study : Clinical Epidemiology
ISSUE 3: September – December 2013 CRC Sabah Newsletter
Activities and Photo Gallery
SABAH RESEARCH DAY 2013
Opening CRC Building by Datuk Dr Jeyaindran Tan Sri Sinnadurai
18 Oct 2013
Opening Ceremony Sabah Research Day 2013 by Datuk Dr Jeyaindran Tan Sri
Sinnadurai 18 Oct 2013.
Poster Visit by Datuk Dr Jeyaindran
Sabah Research Day 2013 : The Speakers Sabah Research Day 2013 : The Secretariat
ISSUE 3: September – December 2013 CRC Sabah Newsletter
Sabah Research Day 2014 Participants
CRC DISTRICT VISIT
Objective: To promote CRC services and to attempt resolve problems in regards to research matters in districts.
CRC District Visit HOSPITAL TAMBUNAN Date: 07 November 2013 Total Participant: 24
CRC District Visit
HOSPITAL RANAU Date: 06 November 2013 Total Participants: 29
ISSUE 3: September – December 2013 CRC Sabah Newsletter
CRC District Visit
HOSPITAL TUARAN Date: 03 December 2013 Total Participants: 15
CRC District Visit
HOSPITAL PAPAR Date: 12 November 2013 Total Participants: 13
NCCR 3-5 SEPT 2013, HOTEL SERI PACIFIC, KUALA LUMPUR
ISSUE 3: September – December 2013 CRC Sabah Newsletter
RESEARCH CAMP ALUMNI 5 SEPT 2013, HOTEL SERI PACIFIC, KUALA LUMPUR
KURSUS PENGENDALIAN SAMPEL MAKMAL (7 NOV 2013), MAKMAL PATOLOGI HQE ll
COLLABORATION MEETTING BETWEEN SPU, UMS and CRC Sabah (21 Nov 2013), UMS Block, QEH
ISSUE 3: September – December 2013 CRC Sabah Newsletter
LAWATAN SAMBIL BELAJAR KE CRC HWKKS 15 NOV 2013
CRC HWKKS APPRECIATION AND CHRISTMAS LUNCH, (21ST DECEMBER 2013) SOUL OUT RESTAURANT, GRAND BORNEO HOTEL
ISSUE 3: September – December 2013 CRC Sabah Newsletter
CONTACT US
Clinical Research Centre Hospital Queen Elizabeth I Locked Bag No 2029 88586 Kota Kinabalu Sabah Tel: 088-517507 Fax: 088-211906 Email: crc.sabah@sbh.moh.gov.my Clinical Research Centre Level 5, Cardiology Clinic Hospital Queen Elizabeth II Lorong Bersatu Off Jalan Damai Luyang 88300 Kota Kinabalu Sabah Tel: 088-324600(2019) Fax: 088-272454 Clinical Research Centre, 7th Floor, Pusat Perubatan Nuklear dan Radioterapi, Hospital Wanita dan Kanak-kanak Sabah (Hospital Likas), 88996 Kota Kinabalu, sabah. Tel:088-522600 (2272)
Fax: 088-435734
RESEARCH CONSULTATION CLINIC
Provide consultation services to facilitate researchers in:
1. Research idea
Literature search
2. Research Proposals
Study Design Sample size Calculation Statistical analysis
3. Data analysis
4. Presentation/Publication/
Consulting services are provided at the CRC Unit. An appointment is required, and maybe made by email or by phone:
crc.sabah@sbh.moh.gov.my
crc_rcc@sbh.moh.gov.my
Tel : 088-517507 or 088-324600 ext 2019
DAY VENUE TIME
Monday
CRC,HQE 8.00am-12.00 noon 2.30pm-4.30 pm
Tuesday
CRC,HQE II 8.00am-12.00 noon 2.30 pm- 4.30 pm
UPCOMING EVENT
1. Good Clinical Practice (GCP) Workshop collaboration with Clinical Research Malaysia (CRM) 19th – 21st Feb 2014, Sabah Women and Children Hospital.
2. Sabah Good Clinical Practice (GCP) Workshop 26th – 28th Mar 2014, Hospital Queen Elizabeth II.
3. Basic to Intermediate Medical Biostatistics Using SPSS Workshop 2014 14 – 17 April 2014, School Of Medical, University Malaysia Sabah (UMS).
4. Advanced Medical Biostatistics Using SPSS Workshop 2014 2 – 6 Jun 2014, School Of Medical, University Malaysia Sabah (UMS).
Recommended